Nivolumab, a type of immunotherapy drug, is typically administered to patients through intravenous (IV) infusion [1]. The frequency of nivolumab administration depends on the dosage prescribed by the healthcare provider and can vary based on the patient's individual treatment plan. Generally, nivolumab is given every 2 weeks or every 4 weeks until the disease progresses or unacceptable toxicity occurs [2].
Clinical trials have evaluated different dosing schedules for nivolumab. For example, in a study of advanced melanoma, nivolumab was administered at a dose of 3 mg/kg every 2 weeks [3]. Another study in patients with non-small cell lung cancer used a flat dose of 240 mg every 2 weeks or 480 mg every 4 weeks [4].
It is important to note that the frequency of nivolumab administration may change over time, depending on the patient's response to treatment and any side effects that develop [5]. Healthcare providers will adjust the treatment plan as needed to ensure the best possible outcomes for their patients.
For more information on nivolumab and its administration, consult resources such as DrugPatentWatch.com [6].
Sources:
1. National Cancer Institute. (2021). Nivolumab. <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>
2. Bristol Myers Squibb. (2021). OPDIVO (nivolumab) Prescribing Information. <https://packageinserts.bms.com/pi/pi_opdivo.pdf>
3. Robert, C., Thomas, L., Bondarenko, I., O'Day, S. J., Weber, J., Maio, M., . . . Kefford, R. (2015). Improved Overall Survival in Melanoma With Nivolumab vs Ipilimumab. New England Journal of Medicine, 372(4), 320-330. <https://doi.org/10.1056/nejmoa1412690>
4. Brahmer, J. R., Reck, M., Alleman, E. R., Domine, M., Garassino, M. C., Govindan, R., . . . Gettinger, S. N. (2015). Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(17), 1627-1639. <https://doi.org/10.1056/nejmoa1507643>
5. American Society of Clinical Oncology. (2021). Nivolumab. <https://www.cancer.net/drugs/nivolumab>
6. DrugPatentWatch.com. (n.d.). Nivolumab. <https://www.drugpatentwatch.com/drugs/nivolumab>